Corcept Therapeutics: Fourth time's a charm for mifepristone in PMD?
CollabRx and Affymetrix partner to develop analytical tools for integrated clinical cancer panels
Vital Therapies aims even lower with $12-per-share IPO
Visit our sites for b2b sales and banking employees:
cafeb2bsales.com
cafebanking.com
Submit an article to cafepharma's CP Wire. Click here to find out more.
| Company | Average | Last 24h |
Increase |
|---|---|---|---|
| West-Ward Pharmaceuticals | 1 | 10 | 900 % |
| Actelion | 1 | 8 | 700 % |
| Bioniche Pharma | 1 | 7 | 600 % |
| Ampio Pharmaceuticals | 1 | 5 | 400 % |
| AP Pharma | 14 | 59 | 321 % |
| Merck Serono | 1 | 4 | 300 % |
| Enanta | 1 | 4 | 300 % |
| Pacific Biosciences | 3 | 12 | 300 % |
| Aetna | 6 | 24 | 300 % |
| A.P. Pharma | 15 | 60 | 300 % |
| Company | Average | Last 24 hrs |
Increase |
|---|---|---|---|
| Digirad | 1 | 13 | 1200 % |
| Zafgen | 1 | 13 | 1200 % |
| Volcano Corporation | 2 | 14 | 600 % |
| Vivakor | 1 | 7 | 600 % |
| Alexza Pharmaceuticals | 2 | 14 | 600 % |
| Codexis | 8 | 49 | 513 % |
| Columbia Laboratories | 3 | 16 | 433 % |
| Actelion | 19 | 100 | 426 % |
| Emdeon | 5 | 26 | 420 % |
| AspenBio | 1 | 5 | 400 % |